drugset / Trial / NCT00192283
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers
Phase 3
Completed
2903 enrolled
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedSingle-groupDouble-blindPrevention
Summary
The purpose of this study is to determine the efficacy of the liquid formulation of CAIVT against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months, attending day care centers in Europe. In addition, the trial provides the opportunity to investigate the effect of CAIV-T on acute otitis media, on healthcare resource utilization and economic resources.
Timeline
- Start
- 2000-09
- Primary completion
- 2002-04
- Completion
- 2002-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FluMist | Vaccine | 0.2 ml | Intranasal |